Improving Overall Survival and Response Rates in HCC With Tumor Targeting

Eleni Gkika, MD, a radiation oncologist at the University Medical Center Freiburg, discusses the future of treatment for patients with advanced hepatocellular carcinoma.

Eleni Gkika, MD, a radiation oncologist at the University Medical Center Freiburg, discusses the future of treatment for patients with advanced hepatocellular carcinoma (HCC).

According to Gkika, sorafenib (Nexavar) is no longer the standard of care for advanced HCC. The IMbrave-150 study (NCT03434379) established the immunotherapy combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) as the current standard of care.

However, Gkika says that results for this combination is still not good in terms in overall survival and response rate. Tumor targeting fields have been found to be effective against several types of aggressive cancers. The HEPANOVA study (NCT03606590) aims to determine if this is correct for advanced HCC as well.